TEAD INHIBITORS AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/855,082, filed May 31, 2019; U.S. Provisional Patent Application No. 62/928,931, filed October 31, 2019; U.S. Provisional Patent Application No. 62/944,567, filed December 6, 2019; and U.S. Provisional Patent Application No. 63/025,219, filed May 15, 2020, the contents of each of which are herein incorporated by reference in their entireties.

TECHNICAL FIELD OF THE INVENTION


[0002] The present invention relates to compounds and methods useful for inhibition of Transcriptional Enhancer Associate Domain (TEAD). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various diseases, disorders, and conditions as described herein.

BACKGROUND OF THE INVENTION

[0003] Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are transcriptional co-activators of the Hippo pathway network and regulate cell proliferation, migration, and apoptosis. Inhibition of the Hippo pathway promotes YAP/TAZ translocation to the nucleus, wherein YAP/TAZ interact with TEAD transcription factors and coactivate the expression of target genes and promote cell proliferation. Hyperactivation of YAP and TAZ and/or mutations in one or more members of the Hippo pathway network have been implicated in numerous cancers.

SUMMARY ~~OF THE INVENTION~~

[0003a] In an aspect of the present disclosure, there is provided a compound of Formula **I**:



I

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is -NH-CH_2- or -NH-C(O)-;

Ring A is phenyl, optionally substituted 1-2 times by halogen, -CN, $–NO_2$, or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or $–NO_2$;

R^2 is -an optionally substituted 5 membered heteroaryl ring having 2 nitrogen atoms;

R^3 is -H;


R^4 is halogen, -$S(O)_2N(R)_2$, -S(O)$N(R)_2$, or -C(O)$N(R)_2$;

R^6 is -H or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or $–NO_2$; and

each R is independently -H or optionally substituted -C_{1-6} aliphatic.

[0003b] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003c] In a further aspect of the present disclosure, there is provided a compound:




I-68

, or a pharmaceutically acceptable salt thereof.

[0003d] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003e] In a further aspect of the present disclosure, there is provided a compound:




I-31

, or a pharmaceutically acceptable salt thereof.

[0003f] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003g] In a further aspect of the present disclosure, there is provided a compound:




I-32

, or a pharmaceutically acceptable salt thereof.

[0003h] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003i] In a further aspect of the present disclosure, there is provided a compound:



I-74

, or a pharmaceutically acceptable salt thereof.

[0003j] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0003k] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cancer in a patient.

[0003l] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting the progress of a cancer in a patient.

[0003m] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, for treating a disease or disorder associated with increased TEAD expression.

[0003n] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder associated with increased TEAD activity.

[0003o] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder in which inhibition of TEAD activity is beneficial.


[0003p] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease or disorder in which Hippo pathway inhibition is beneficial.

[0003q] In a further aspect of the present disclosure, there is provided a compound disclosed herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

[0004] The Hippo signaling cascade is an important pathway for cancer biogenesis and tumor maintenance. The Hippo pathway is heavily mutated across many cancer indications through loss of function mutations in genes such as NF2. These pro-tumor mutations lead to the constitutive activation of the downstream transcriptional coactivators YAP and TAZ that drive the expression of many pro-survival and proliferation genes through the essential interaction with a TEAD protein


family member. In addition, this unrestrained transcriptional program drives enhanced immune suppression in the tumor microenvironment. As described herein, to target this oncogenic pathway novel small molecule inhibitors were identified that selectively bind to TEAD and disrupt their interaction with YAP and TAZ, thereby downregulating YAP- and TAZ-dependent transcription. As demonstrated herein, these TEAD inhibitors prevent TEAD palmitoylation, which is critical for the interaction between YAP and TEAD. Furthermore, the TEAD inhibitors described herein inhibit *in vitro* proliferation of YAP-dependent (*i.e.*, Hippo pathway-deficient cancer cell lines), but not Hippo pathway wild type cancer cell lines. Importantly, as shown herein, the TEAD inhibitor compounds of the present ~~invention~~ disclosure did not affect survival of a differentiated mouse podocyte cell line or compromise mouse kidney histology. Subsequent experiments *in vivo* demonstrate the TEAD inhibitors described herein downregulate YAP-dependent genes in human tumor xenografts after oral dosing. In addition, the TEAD inhibitors described herein exhibit single agent tumor growth inhibition of human tumor xenografts in mice at well tolerated oral doses. The data described herein demonstrate the ability of the small molecule TEAD inhibitors provided herein for targeting the Hippo pathway in cancers.

[0005] It has now been found that compounds of the present ~~invention~~disclosure, and pharmaceutically acceptable compositions thereof, are effective as TEAD inhibitors. In one ~~aspect~~example, the present ~~invention~~ disclosure provides a compound of Formula **I'**:



I'

or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein. In one ~~aspect~~example, the present ~~invention~~ disclosure provides a compound of Formula **I**:



I


or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein.

[0006] Compounds of the present ~~invention~~disclosure, and pharmaceutically acceptable salts and compositions thereof, are useful for treating a variety of diseases, disorders or conditions

CLAIMS

What is claimed is:

1. A compound of Formula **I**:



I

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is -NH-CH_2- or -NH-C(O)- ~~C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -N(R)-, -O-, -CH(OR)-, -CH(SR)-, -CH(N(R)$_2$)-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, -N(R)C(O)N(R)-, -S-, -SO-, -SO_2-, -SO_2N(R)-, -(R)NSO_2-, -C(S)-, -C(S)O-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, or -(R)NC(S)N(R)-~~;

Ring A is phenyl, ~~a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic carbocyclic ring, or a 4-, 5-, or 6- membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A is~~ optionally substituted 1-2 times by halogen, -CN, –NO_2, or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or –NO_2;

R^2 is ~~-H, or~~ an optionally substituted ~~4-,~~ 5~~-, or 6-~~ membered heteroaryl ring having ~~1,~~ 2~~, 3, or 4 heteroatoms independently selected from~~ nitrogen atoms~~, oxygen, or sulfur~~;

R^3 is -H;

R^4 is ~~-H,~~ halogen, -$S(O)_2N(R)_2$, -S(O)N$(R)_2$, or -C(O)N$(R)_2$;

R^6 is -H or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or –NO_2; and

each R is independently -H or optionally substituted -C_{1-6} aliphatic.

~~2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L^1 is C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -O-, -CH(OR)-, -CH(N(R)$_2$)-, -C(O)-, -C(O)O-, -OC(O)-, -N(R)-, -C(O)N(R)-, -(R)NC(O)-, -OC(O)N(R)-, -(R)NC(O)O-, or -N(R)C(O)N(R)-.~~

~~3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein L^1 is C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -N(R) -.~~

~~4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein L^1 is -N(R)- or -N(R)-CH_2-.~~

~~5~~2. The compound of claim ~~3~~1, or a pharmaceutically acceptable salt thereof, wherein L^1 is ~~–NH- or~~ –NH-CH_2-.


~~6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl, optionally substituted 1-2 times by halogen, -CN, $-NO_2$, or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or $-NO_2$.~~

~~7~~3. The compound of claim ~~6~~1, or a pharmaceutically acceptable salt thereof, wherein Ring A is phenyl, optionally substituted 1-2 times by -C_{1-6} aliphatic substituted 0-6 times by halogen.

~~8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-2 times by halogen, -CN, $-NO_2$, or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or $-NO_2$.~~

~~9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein Ring A is a 6-membered monocyclic heteroaromatic ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, optionally substituted 1-2 times by -C_{1-6} aliphatic substituted 0-6 times by halogen.~~

~~10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein Ring A~~




~~is , R^1 is hyrdogen, and R^7 is -C_{1-6} aliphatic substituted 1, 2, 3, 4, 5, or 6 times by F.~~

~~11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is an optionally substituted 4-, 5-, or 6- membered ring having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

~~12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen.~~

~~13~~4. The compound of claim ~~12~~1, or a pharmaceutically acceptable salt thereof, wherein R^2 is




, and R is unsubstituted -C_{1-6} aliphatic.

~~14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is -$S(O)_2N(R)_2$.~~

~~15~~5. The compound of claim ~~14~~1, or a pharmaceutically acceptable salt thereof, wherein R^4 is -$S(O)_2NHR$.

~~16~~6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is –H.


~~17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula **(II)**:~~




~~**(II)**~~

~~wherein R^1 is H, and R^7 is -C_{1-6} aliphatic substituted 0-6 times by halogen.~~


~~187~~. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(IXa-1)**, ~~or~~ **(IXa-2)** , **(Xa-1)**, or **(Xa-2)**:




IXa-1



IXa-2




Xa-1




Xa-2

wherein L^1 is -NH-CH_2-, and each R is independently -H or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or –N~~-a C_{2-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-~~.

~~19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(Xa-1)** or **(Xa-2)**:~~




~~**Xa-1**~~




~~**Xa-2**~~

~~wherein L^1 is a C_{2-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-.~~

~~208~~. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XIa-1)** or **(XIa-2)**:




XIa-1




XIa-2

wherein L^1 is -NH-CH_2-, and each R is independently -H or -C_{1-6} aliphatic substituted 0-6 times by halogen, -CN, or –NO_2~~a C_{2-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-~~.

~~2~~19. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XIIa-1)** or **(XIIa-2)**:




XIIa-1




XIIa-2

wherein L^1 is -NH-CH_2-~~a C_{2-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-~~, and R is -C_{1-3} aliphatic substituted 1, 2, 3, 4, 5, or 6 times by –F.

~~22~~10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XIIIa-1)** or **(XIIIa-2)**:




XIIIa-1




XIIIa-2

wherein L^1 is ~~a C_{2-6} bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -~~NH-CH_2-, and R is optionally substituted -C_{1-6} aliphatic.

1123. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XIVa-1)** or **(XIVa-2)**:




XIVa-1




XIVa-2

wherein L^1 is ~~a C_{2-6} bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with~~ -NH-CH_2-.

1224. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XVa-1)** or **(XVa-2)**:




XVa-1




XVa-2

~~wherein R^2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen~~.

2513. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XVIa-1)** or **(XVIa-2)**:




XVIa-1



XVIa-2.


~~26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(IXb)** or **(IXc)**:~~



IXb **IXc**

wherein L^1 is a C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-.

27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(Xb)** or **(Xc)**:



Xb **Xc**

wherein L^1 is a C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -N(R)-.



28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is Formula **(XIb)** or **(XIc)**:



XIb **XIc**

wherein L^1 is a C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-.



29. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is Formula **(XIIb)** or **(XIIc)**:

~~**XIIb** **XIIc**~~

~~wherein L^1 is a C_{1-6} bivalent straight or branched hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, and R is C_{1-3} aliphatic substituted 1, 2, 3, 4, 5, or 6 times by -F.~~



~~30. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is Formula **(XIIIb)** or **(XIIIc)**:~~

~~**XIIIb** **XIIIc**~~

~~wherein L^1 is a C_{1-6} bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-, and R is optionally substituted C_{1-6} aliphatic.~~



~~31. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is Formula **(XIVb)** or **(XIVc)**:~~

~~**XIVb** **XIVc**~~

~~wherein L^1 is a C_{1-6} bivalent straight hydrocarbon chain wherein 1 methylene unit of the chain is replaced with -NH-.~~


~~32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula **(XVb)** or **(XVc)**:~~

~~XVb XVc~~










~~wherein R^2 is an optionally substituted 5-membered ring having 1, 2, 3, or 4 nitrogen.~~



~~33. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (XVIb) or (XVIc):~~



~~XVIb XVIc.~~


~~34~~14. The compound of ~~any one of the preceding~~ claim~~s~~ 1, which is selected from~~:~~ ~~the compounds of Table 1~~

I-27 	I-29 	I-31 
I-32 	I-41 	I-42 
I-46 	I-50 	I-51 
I-68, and	I-74	

, or a pharmaceutically acceptable salt thereof.


15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II):



(II)

wherein L^1 is -NH-CH_2-, R^1 is -H, -halogen, -CN, –NO_2, or -C_{1-6} aliphatic, and R^7 is -H, -halogen, -CN, –NO_2, or -C_{1-6} aliphatic.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is




.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is -$S(O)_2$NH-CH_3.

~~35~~18. A pharmaceutical composition comprising a compound of any one of ~~the preceding~~ claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

19. A compound:




I-68

, or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising the compound of claim 19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

21. A compound:




I-31

, or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising the compound of claim 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

23. A compound:




I-32

, or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising the compound of claim 23, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. A compound:



I-74

, or a pharmaceutically acceptable salt thereof.

26. A pharmaceutical composition comprising the compound of claim 25, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

~~36. A method for treating cancer in a patient, comprising administering to the patient a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~37. The method of claim 36, wherein the cancer is associated with increased TEAD expression.~~

~~38. The method of claims 36 or 37, wherein the cancer is associated with increased TEAD activity.~~

~~39. A method for inhibiting the progress of cancer in a patient, comprising administering to the patient a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~40. The method of claim 39, wherein the cancer is associated with increased TEAD expression.~~

~~41. The method of claims 39 or 40, wherein the cancer is associated with increased TEAD activity.~~

~~42. A method of treating a patient having a disease or disorder associated with increased TEAD expression comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~43. A method of treating a patient having a disease or disorder associated with increased TEAD activity comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~44. A method of treating a disease or disorder in which inhibition of TEAD activity is beneficial comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~45. A method of treating a disease or disorder in which Hippo pathway inhibition is beneficial comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-34, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 35.~~

~~46. The method of any one of claims 42-45, wherein the disease or disorder is a cellular proliferative disorder.~~

~~47. The method of claim 46, wherein the cellular proliferative disorder is cancer.~~

~~48. The method of any one of claims 36-41 and 47, wherein the cancer is a cancer in which YAP is localized in the nucleus of cells of the cancer.~~

~~49. The method of any one of claims 37, 38, and 40-44, wherein the increased TEAD expression or increased TEAD activity is increased TEAD1 expression or increased TEAD1 activity.~~

~~50. The method of any one of claims 37, 38, and 40-44, wherein the increased TEAD expression or increased TEAD activity is increased TEAD2 expression or increased TEAD2 activity.~~

~~51. The method of any one of claims 37, 38, and 40-44, wherein the increased TEAD expression or increased TEAD activity is increased TEAD3 expression or increased TEAD3 activity.~~

~~52. The method of any one of claims 37, 38, and 40-44, wherein the increased TEAD expression or increased TEAD activity is increased TEAD4 expression or increased TEAD4 activity.~~

~~53. The method of any one of claims 37, 38, and 40-44, wherein the increased TEAD expression or increased TEAD activity is increased TEAD1 expression or increased TEAD1 activity; increased TEAD2 expression or increased TEAD2 activity; increased TEAD3 expression or increased TEAD3 activity; increased TEAD4 expression or increased TEAD4 activity; or any combination thereof.~~

~~54~~27. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ in the manufacture of a medicament for treating a cancer in a patient.

~~55~~28. The use of claim ~~54~~27, wherein the cancer is associated with increased TEAD expression.

~~56~~29. The use of claim 27~~s 54 or 55~~, wherein the cancer is associated with increased TEAD activity.

~~57~~30. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ in the manufacture of a medicament for inhibiting the progress of a cancer in a patient.

~~58~~31. The use of claim ~~57~~30, wherein the cancer is associated with increased TEAD expression.

~~59~~32. The use of claim 30~~s 57 or 58~~, wherein the cancer is associated with increased TEAD activity.

~~60~~33. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ for treating a disease or disorder associated with increased TEAD expression.

~~61~~34. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ in the manufacture of a medicament for treating a disease or disorder associated with increased TEAD activity.

~~62~~35. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ in the manufacture of a medicament for treating a disease or disorder in which inhibition of TEAD activity is beneficial.

~~63~~36. ~~A u~~Use of a compound of any one of claims 1-~~34~~17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, ~~or a pharmaceutical composition of claim 35,~~ in the manufacture of a medicament for treating a disease or disorder in which Hippo pathway inhibition is beneficial.

~~64~~37. The use of any one of claims ~~60~~33-~~63~~36, wherein the disease or disorder is a cellular proliferative disorder.

~~65~~38. The use of claim ~~64~~37, wherein the cellular proliferative disorder is cancer.

~~66~~39. The use of any one of claims ~~54~~27-~~57~~ 30 and ~~65~~38, wherein the cancer is a cancer in which YAP is localized in the nucleus of cells of the cancer.

~~67~~40. The use of any one of claims ~~55~~28, ~~56~~29, and ~~58~~31-~~62~~35, wherein the increased TEAD expression or increased TEAD activity is increased TEAD1 expression or increased TEAD1 activity.

~~68~~41. The use of any one of claims ~~55~~28, ~~56~~29, and ~~58~~31-~~62~~35, wherein the increased TEAD expression or increased TEAD activity is increased TEAD2 expression or increased TEAD2 activity.

~~69~~42. The use of any one of claims ~~55~~28, ~~56~~29, and ~~58~~31-~~62~~35, wherein the increased TEAD expression or increased TEAD activity is increased TEAD3 expression or increased TEAD3 activity.

~~70~~43. The use of any one of claims ~~55~~28, ~~56~~29, and ~~58~~31-~~62~~35, wherein the increased TEAD expression or increased TEAD activity is increased TEAD4 expression or increased TEAD4 activity.

~~71~~44. The use of any one of claims ~~55~~28, ~~56~~29, and ~~58~~31-~~62~~35, wherein the increased TEAD expression or increased TEAD activity is increased TEAD1 expression or increased TEAD1 activity; increased TEAD2 expression or increased TEAD2 activity; increased TEAD3 expression or increased TEAD3 activity; increased TEAD4 expression or increased TEAD4 activity; or any combination thereof.

~~45.~~ A compound of any one of claims 1-17, 19, 21, 23, or 25, or a pharmaceutically acceptable salt thereof, for use in therapy.